Skip to main content
. 2020 Jun 1;21(1):61. doi: 10.1186/s10194-020-01127-0

Table 3.

Changes in HIT-6 headache disability categories after three and six erenumab treatments

Baseline (N = 162) N (%) Month 3 (N = 100) N (%) Month 6 (N = 73) N (%)
Severe impact (60–78) 156 (96%) 68 (68%) 43 (59%)
Substantial impact (56–59) 5 (3%) 3 (3%) 14 (19%)
Some impact (50–55) 1 (1%) 15 (15%) 11 (16%)
Little or no impact (< 48) 0 (0%) 14 (14%) 5 (6%)

HIT-6, headache impact test-6; N, number